The Genetics of Alzheimer Disease
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Family history is the second strongest risk factor for Alzheimer disease (AD) following advanced age.Twin and family studies indicate that genetic factors are estimated to play a role in at least 80% of AD cases.The inheritance of AD exhibits a dichotomous pattern.On one hand, rare mutations in APP, PSEN1, and PSEN2 virtually guarantee early-onset (,60 years) familial AD, which represents 5% of AD.On the other hand, common gene polymorphisms, such as the 14 and 12 variants of the APOE gene, can influence susceptibility for 50% of the common late-onset AD.These four genes account for 30% -50% of the inheritability of AD.Genome-wide association studies have recently led to the identification of 11 additional AD candidate genes.This paper reviews the past, present, and future attempts to elucidate the complex and heterogeneous genetic underpinnings of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“To date, 228 PSEN1 mutations have been identified causing ADAD (49, 303, 304, 440, 566, 580).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [580]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“CLU gene encodes clusterin or APOJ that besides its functions in lipid transport, membrane recycling, cell adhesion, and apoptosis (90, 444, 600, 677) affects transvascular A 𝛃 clearance by promoting A 𝛃 42 efflux across the BBB (580).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [580]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PSEN1 mutations lead to faster soluble-to-fibrillar conversion of A 𝛃 42 promoting amyloid deposition in the brain (303, 566, 580).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [580]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Autosomal-dominant AD (ADAD) is an inherited form of AD caused by mutations in amyloid precursor protein ( APP ) and presenilin-1 and 2 ( PSEN1; PSEN2 ) genes (49, 177, 303, 304, 580).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [580]
The cited source says what the claim attributes to it.
In the citing paper
“APOE4 is the major genetic risk factor for sporadic, late-onset AD (199, 368, 580, 612).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [580]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 3×
“Goate et al. (1991), then resequenced the same two APP exons to reveal the first EO-FAD mutation (London mutation; V717I) in APP.”
BackgroundThe precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619 · cited 1×
“In 1987, we as well as others isolated the amyloid b (A4) protein precursor (APP; Goldgaber et al. 1987; Kang et al. 1987; Tanzi et al. 1987a, 1988) and mapped it to chromosome 21.”
BackgroundCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051 · cited 3×
“1987b); they were ultimately demonstrated to carry PSEN1 mutations (Sherrington et al. 1995).”
BackgroundSelf-citationHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 14×
“Genetic association studies remain the most common method for identifying novel LOAD genes and are most often employed in the form of large-scale GWASs that screen the entire human genome for novel disease loci.”
InfluentialScheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599 · cited 3×
“Whether EO-FAD mutations appear in APP near the g-secretase cleavage site or in the presenilins, the vast majority of them serve to increase the ratio of Ab42:Ab40. g-Secretase modulators are aimed at reversing this ratio and represent very promising compounds for treating and preventing AD based on what has been garn…”
BackgroundSelf-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577 · cited 1×
“Shortly thereafter, we first reported a homolog of PSEN1 called presenilin (PSEN2; Levy-Lahad et al. 1995) on chromosome 1 and showed that it harbors the N141I mutation in Volga-German EO-FAD families.”
BackgroundSelf-citationGenome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Research works printed but not linked: 2
- Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, Zis- mann VL, Joshipura KD, Pearson JV, Hu-Lince D, Huen- telman MJ, et al. 2007. Papassotiropoulos A, Stephan DA. GAB2 alleles modify Alzheimer's risk in APOE 14 car- riers. Neuron 54: 713 -720.
- Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. 1993. Apolipopro- tein E: High-avidity binding to b-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci 90: 1977-1981.
Cited by
Items 301–400 of 804
Tan, Z., Garduño, B. M., Fernández‐Aburto, P., Chen, L., Ha, N. M.-L., Cogram, P., Holmes, T. C., & Xu, X. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01481-x · Cited by 30
Kaneko, R., Matsui, A., Watanabe, M., Harada, Y., Kanamori, M., Awata, N., Kawazoe, M., Takao, T., Kobayashi, Y., Kikutake, C., et al. (2023) · Inflammation and Regeneration · doi:10.1186/s41232-023-00257-7 · Cited by 30
Relevance of the COPI complex for Alzheimer’s disease progression in vivo
Bettayeb, K., Hooli, B. V., Parrado, A., Randolph, L. K., Varotsis, D. F., Aryal, S., Gresack, J. E., Tanzi, R. E., Greengard, P., & Flajolet, M. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604176113 · Cited by 32
Self-citationGenetic variation associated with the occurrence and progression of neurological disorders
Little, J., Barakat, C., Martino, R., Pringsheim, T. M., Tremlett, H. L., McKay, K. A., Lieshout, P. H. H. M. V., Walsh, S. J., Gomes, J., & Krewski, D. R. (2016) · NeuroToxicology · doi:10.1016/j.neuro.2016.09.018 · Cited by 30
Into the Fourth Dimension: Dysregulation of Genome Architecture in Aging and Alzheimer’s Disease
Winick‐Ng, W., & Rylett, R. J. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00060 · Cited by 31
Moir, R. D., & Tanzi, R. E. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00070 · Cited by 32
Self-citationLv, J., Wang, W., Zhu, X., Xu, X., Yan, Q., Lu, J., Shi, X., Wang, Z., Zhou, J., Huang, X., et al. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.07.041 · Cited by 30
Revealing the Molecular Mechanisms of Alzheimer’s Disease Based on Network Analysis
Bayraktar, A., Lam, S. C. C., Altay, Ö., Li, X., Yuan, M., Zhang, C., Arif, M., Türkez, H., Uhlén, M., Shoaie, S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111556 · Cited by 37
Personalized Biochemistry and Biophysics
Kroncke, B. M., Vanoye, C. G., Meiler, J., George, A. L., & Sanders, C. R. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00189 · Cited by 29
Is It the Twilight of BACE1 Inhibitors?
Hrabinova, M., Pejchal, J., Kucera, T., Jun, D., Schmidt, M., & Soukup, O. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200503023323 · Cited by 28
“Thus, understanding of APP processing appears fundamental for the development of a therapeutic strategy aimed at reducing Aβ levels in AD patients [21-25].”
BackgroundTran, K. M., Kwang, N. E., Butler, C. A., Gomez-Arboledas, A., Kawauchi, S., Mar, C., Chao, D., Barahona, R. A., Da Cunha, C., Tsourmas, K. I., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00793-x · Cited by 28
“Genetic factors can determine an individual’s susceptibility to AD, with rare autosomal dominant AD (ADAD) cases manifest - ing within families carrying pathogenic variants of Amyloid Precursor Protein (APP), Presenilin 1 (PSEN1), and Presenilin 2 (PSEN2) genes [2–7].”
Fominykh, V., Shadrin, A. A., Jaholkowski, P. P., Bahrami, S., Athanasiu, L., Wightman, D. P., Uffelmann, E., Posthuma, D., Selbæk, G., Dale, A. M., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106174 · Cited by 30
Genetic and epigenetic targets of natural dietary compounds as anti-Alzheimer’s agents
Ordoñez, W. O. C., Cajas‐Salazar, N., & Velasco-Reyes, M. A. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.382232 · Cited by 29
A presenilin 1 mutation in the first case of Alzheimer's disease: Revisited
Rupp, C., Beyreuther, K. T., Maurer, K., & Kins, S. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.06.005 · Cited by 28
Montero‐Calle, A., Segundo‐Acosta, P. S., Garranzo‐Asensio, M., Rábano, A., & Barderas, R. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01809-0 · Cited by 39
Lutz, B. M., & Peng, J. (2018) · Proteomes · doi:10.3390/proteomes6040046 · Cited by 27
“Genetic analysis of AD patients established three causative genes (APP, PSEN1 and PSEN2) and a high-risk allele (ApoE ε4) [5,6], whereas genome-wide association studies led to the discovery of more than 20 low-risk genetic loci [7–9], and more recently, high-throughput sequencing identified rare, medium-risk genes, su…”
BackgroundValdes, P., Caldwell, A. B., Liu, Q., Fitzgerald, M. Q., Ramachandran, S., Karch, C. M. M., Dominantly Inherited Alzheimer Network (DIAN), Adams, S., Allegri, R., Araki, A., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01659-6 · Cited by 28
Do, H. N., Devkota, S., Bhattarai, A., Wolfe, M. S., & Miao, Y. (2023) · Communications Biology · doi:10.1038/s42003-023-04539-1 · Cited by 31
Guzmán, E. A., Bouter, Y., Richard, B. C., Lannfelt, L., Ingelsson, M., Paetau, A. E., Verkkoniemi‐Ahola, A., Wirths, O., & Bayer, T. A. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-13 · Cited by 34
Jović, M., Lončarević‐Vasiljković, N., Ivković, S., Dinić, J., Milanović, D., Zloković, B. V., & Kanazir, S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0216726 · Cited by 29
Mezencev, R., & Chernoff, Y. O. (2020) · Cancers · doi:10.3390/cancers12040796 · Cited by 28
Santos, G., Díaz, M. L., & Torres, N. V. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00090 · Cited by 27
Poursaei, E., Abolghasemi, M., Bornehdeli, S., Shanehbandi, D., Asadi, M., Sadeghzadeh, M., Rahmanpour, D., & Sadeh, R. N. (2021) · Psychiatric Genetics · doi:10.1097/ypg.0000000000000303 · Cited by 26
Proteomic Exploration of Paraoxonase 1 Function in Health and Disease
Jakubowski, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097764 · Cited by 26
Aβ-Degrading Proteases: Therapeutic Potential in Alzheimer Disease
Leissring, M. A. (2016) · CNS Drugs · doi:10.1007/s40263-016-0364-1 · Cited by 24
Dual Role of NMDAR Containing NR2A and NR2B Subunits in Alzheimer’s Disease
Raïch, I., Lillo, J., Rebassa, J. B., Capó, T., Cordomí, A., Reyes‐Resina, I., Pallàs, M., & Navarro, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094757 · Cited by 28
Peripheral Pathways to Neurovascular Unit Dysfunction, Cognitive Impairment, and Alzheimer’s Disease
Nelson, A. R. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.858429 · Cited by 25
Zheng, C., Liu, S., Zhang, X., Hu, Y., Shang, X., Zhu, Z., Huang, Y., Wu, G., Xiao, Y., Du, Z., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.880576 · Cited by 25
An evolutionary perspective on complex neuropsychiatric disease
McClellan, J., Zoghbi, A. W., Buxbaum, J. D., Cappi, C., Crowley, J. J., Flint, J., Grice, D. E., Gülsüner, S., Iyegbe, C. O., Jain, S., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.10.037 · Cited by 25
Sirtuins as Modifiers of Huntington's Disease (HD) Pathology
Neo, S. H., & Tang, B. L. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.11.013 · Cited by 25
Ştefănescu, R., Stanciu, G. D., Luca, A., Caba, I.-C., Tamba, B.-I., & Mihai, C. T. (2019) · Molecules · doi:10.3390/molecules24061167 · Cited by 26
Unraveling the genes implicated in Alzheimer's disease
Giri, M., Shah, A., Upreti, B., & Rai, J. C. (2017) · Biomedical Reports · doi:10.3892/br.2017.927 · Cited by 27
New opportunities for antioxidants in amelioration of neurodegenerative diseases
Bhandari, U. R., Danish, S. M., Ahmad, S., Ikram, M., Nadaf, A., Hasan, N., Kesharwani, P., & Ahmad, F. J. (2024) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2024.111961 · Cited by 26
The emerging role of the microbiome in Alzheimer's disease
Wasén, C., Simonsen, E., Ekwudo, M. N., Profant, M. R., & Cox, L. M. (2022) · International review of neurobiology · doi:10.1016/bs.irn.2022.09.001 · Cited by 25
Sauty, B., & Durrleman, S. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1161527 · Cited by 26
Koutseff, A., Mittelhaeuser, C., Essabri, K., Auwerx, J. H., & Méziane, H. (2013) · Brain Research · doi:10.1016/j.brainres.2013.10.003 · Cited by 24
X11/Mint Genes Control Polarized Localization of Axonal Membrane Proteins in Vivo
Gross, G. G., Lone, G. M., Leung, L. K., Hartenstein, V., & Guo, M. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.5749-12.2013 · Cited by 25
Early detection and personalized medicine: Future strategies against Alzheimer's disease
Meco, A. D., & Vassar, R. J. (2020) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.10.002 · Cited by 29
Li, M., Pehar, M., Liu, Y., Bhattacharyya, A., Zhang, S.-C., O'Riordan, K. J., Burger, C., D'Adamio, L., & Puglielli, L. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.06.021 · Cited by 23
The Spectrum of Genetic Risk in Alzheimer Disease
Karagas, N. E., Young, J. E., Blue, E., & Jayadev, S. (2025) · Neurology Genetics · doi:10.1212/nxg.0000000000200224 · Cited by 25
Pauls, E., Bayod, S., Mateo, L., Alcalde, V., Juan-Blanco, T., Sánchez‐Soto, M., Saido, T. C., Saito, T., Berenguer, A., Attolini, C. S., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00983-y · Cited by 25
Harrison, J. R., Foley, S. F., Baker, E. A., Bracher‐Smith, M., Holmans, P., Stergiakouli, E., Linden, D. E. J., Caseras, X., Jones, D. K., & Escott‐Price, V. (2023) · Brain Communications · doi:10.1093/braincomms/fcad229 · Cited by 23
Wu, Z., Tao, Q., Chen, Y., Liu, Z., Sun, Y., Yang, P., Lu, S.-J., Xu, M., Yang, J., & Dong, Q. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s62554 · Cited by 23
Ethical issues in neurogenetics
Uhlmann, W. R., & Roberts, J. S. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63233-3.00003-8 · Cited by 23
In search of pathogenic amyloid β-peptide in familial Alzheimer's disease
Wolfe, M. S. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.07.002 · Cited by 23
Wang, Y., Song, X., Wang, Y., Huang, L., Luo, W., Li, F., Qin, S., Wang, Y., Xiao, J., Wu, Y., et al. (2020) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2020.1794789 · Cited by 24
Bellver‐Sanchís, A., Pallàs, M., & Griñán‐Ferré, C. (2021) · Epigenomes · doi:10.3390/epigenomes5020015 · Cited by 25
Effects of apolipoprotein E isoform, sex, and diet on insulin BBB pharmacokinetics in mice
Rhea, E. M., Hansen, K. M., Pemberton, S., Torres, E. R. S., Holden, S. J., Raber, J., & Banks, W. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-98061-1 · Cited by 23
Alzarea, E. A., Al-Kuraishy, H. M., Al-Gareeb, A. I., Alexiou, A. T., Papadakis, M., Beshay, O. N., & Batiha, G. E. (2025) · NeuroMolecular Medicine · doi:10.1007/s12017-025-08832-6 · Cited by 23
Human stem cell models of dementia
Livesey, F. J. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu302 · Cited by 22
Witucki, Ł., & Jakubowski, H. (2023) · Cells · doi:10.3390/cells12050746 · Cited by 23
O’Day, D. H. (2024) · Biomolecules · doi:10.3390/biom14020173 · Cited by 22
Dehury, B., Somavarapu, A. K., & Kepp, K. P. (2020) · Journal of Structural Biology · doi:10.1016/j.jsb.2020.107648 · Cited by 22
Wu, J., & Jackson, L. E. (2021) · Earth · doi:10.3390/earth2010009 · Cited by 24
VEGF-A-related genetic variants protect against Alzheimer’s disease
Petrelis, A. M., Stathopoulou, M. G., Kafyra, M., Murray, H. A., Masson, C., Lamont, J. V., FitzGerald, P. S., Dedoussis, G. V., Yen, F. T., & Visvikis‐Siest, S. (2022) · Aging · doi:10.18632/aging.203984 · Cited by 23
Presenilin, γ-Secretase, and the Search for Pathogenic Triggers of Alzheimer’s Disease
Wolfe, M. S. (2025) · Biochemistry · doi:10.1021/acs.biochem.4c00830 · Cited by 21
Non-Pharmacological Therapeutic Options for the Treatment of Alzheimer’s Disease
Huynh, Q., Elangovan, S., & Holsinger, R. M. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911037 · Cited by 22
Zhu, J., Liu, S., Walker, K. A., Zhong, H., Ghoneim, D. H., Zhang, Z., Surendran, P., Fahle, S., Butterworth, A. S., Alam, M. A., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01378-4 · Cited by 24
Mishra, K. A., & Sethi, K. K. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400748 · Cited by 23
Biomarker-Driven Therapeutic Management of Alzheimer’s Disease: Establishing the Foundations
Cummings, J. L., & Zhong, K. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.205 · Cited by 22
A Human-Based Integrated Framework forAlzheimer’s Disease Research
Pistollato, F., Cavanaugh, S. E., & Chandrasekera, P. C. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150281 · Cited by 23
Ontiveros‐Torres, M. Á., Labra‐Barrios, M. L., Díaz-Cintra, S. Y., Aguilar-Vázquez, A. R., Moreno-Campuzano, S., Flores-Rodríguez, P., Luna-Herrera, C., Mena, R., Perry, G. L., Florán, B., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150837 · Cited by 22
Dougherty, R. J., Lindheimer, J. B., Stegner, A. J., Riper, S. M. V., Okonkwo, O. C., & Cook, D. B. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170576 · Cited by 21
The Genetics of Alzheimer’s Disease in the Chinese Population
Gan, C., Zhang, T., & Lee, T. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072381 · Cited by 21
Neprilysin Confers Genetic Susceptibility to Alzheimer’s Disease in Han Chinese
Wang, H.-Z., Bi, R., Zhang, D., Li, G., Ma, X., Fang, Y., Li, T., Zhang, C., & Yao, Y. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9411-z · Cited by 21
Huang, Y., Hu, Y., Jin, Z., & Shen, Z. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.07.152 · Cited by 21
Papadopoulos, N., Suelves, N., Perrin, F., Vadukul, D. M., Vrancx, C., Constantinescu, S. N., & Kienlen-Campard, P. (2022) · Biomedicines · doi:10.3390/biomedicines10112753 · Cited by 20
INPP5D/SHIP1: Expression, Regulation and Roles in Alzheimer’s Disease Pathophysiology
Olufunmilayo, E. O., & Holsinger, R. M. D. (2023) · Genes · doi:10.3390/genes14101845 · Cited by 20
Physiopathological mechanisms underlying Alzheimer’s disease: a narrative review
Engelhardt, E., Resende, E. D. P. F., & Gomes, K. B. (2024) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2024-vr01 · Cited by 25
Cytoplasmic HDAC4 recovers synaptic function in the 3×Tg mouse model of Alzheimer's disease
Colussi, C., Aceto, G., Ripoli, C., Bertozzi, A., Puma, D. D. L., Paccosi, E., D’Ascenzo, M., & Grassi, C. (2022) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12861 · Cited by 21
Phytocannabinoids as Potential Multitargeting Neuroprotectants in Alzheimer’s Disease
Rathod, S., & Agrawal, Y. O. (2023) · Current Drug Research Reviews · doi:10.2174/2589977515666230502104021 · Cited by 21
Lampert, E. J., Choudhury, K. R., Hostage, C. A., Petrella, J. R., Doraiswamy, P. M., & Initiative, T. A. D. N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060747 · Cited by 21
Lau, J. K. Y., Tian, M., Shen, Y., Lau, S., Fu, W., Fu, A. K. Y., & Ip, N. Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-83932-4 · Cited by 22
Distinct X-chromosome SNVs from some sporadic AD samples
Gómez‐Ramos, A., Podlesniy, P., Soriano, E., & Ávila, J. (2015) · Scientific Reports · doi:10.1038/srep18012 · Cited by 22
Ghosh, A. K., Brindisi, M., Yen, Y., Cárdenas, E. L., Ella‐Menye, J., Kumaragurubaran, N., Huang, X., Tang, J., & Mesecar, A. D. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.04.011 · Cited by 21
Etiology, pathogenesis of Alzheimer's disease and amyloid beta hypothesis
Kamble, S. M., Patil, K. R., & Upaganlawar, A. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00022-4 · Cited by 24
Gao, M., Wang, X., Su, S., Feng, W., Lai, Y., Huang, K., Cao, D., & Wang, Q. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01595 · Cited by 20
Caskey, C. T., Gonzalez‐Garay, M. L., Pereira, S., & McGuire, A. L. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-111212-144716 · Cited by 19
Petrushina, I., Davtyan, H., Hovakimyan, A., Davtyan, A., Passos, G. F., Cribbs, D. H., Ghochikyan, A., & Agadjanyan, M. G. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.002 · Cited by 20
Towards developing a rhesus monkey model of early Alzheimer's disease focusing on women's health
Beckman, D., & Morrison, J. H. (2021) · American Journal of Primatology · doi:10.1002/ajp.23289 · Cited by 19
Ng, B., Rowland, H. A., Wei, L., Arunasalam, K., Hayes, E. M., Koychev, I. G., Hedegaard, A., Ribé, E. M., Chan, D., Chessell, T., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac267 · Cited by 19
Alzheimer’s Disease and Paraoxonase 1 (PON1) Gene Polymorphisms
Saeidi, M., Shakeri, R., Marjani, A., & Khajeniazi, S. (2017) · The Open Biochemistry Journal · doi:10.2174/1874091x01711010047 · Cited by 19
Miller, S., Dhodapkar, R. M., Sutova, H. E., Yao, X., Lee, S., Logan, R., Ran, C., Bhatta, S., Gomm, A., Ju, I. G., et al. (2025) · Science Advances · doi:10.1126/sciadv.ads5006 · Cited by 18
Self-citationNavarro‐Hortal, M. D., Romero‐Márquez, J. M., Osta, S., Jiménez-Trigo, V., Muñoz-Ollero, P., & Varela‐López, A. (2022) · Diseases · doi:10.3390/diseases10020028 · Cited by 19
Evolutionary and genomic perspectives of brain aging and neurodegenerative diseases
Dames, B. A. R., Kilili, H., Charvet, C. J., Díaz-Barba, K., Proulx, M. J., de Sousa, A. A., & Urrutia, A. O. (2023) · Progress in brain research · doi:10.1016/bs.pbr.2022.10.004 · Cited by 19
Spitz, S., Schobesberger, S., Brandauer, K., & Ertl, P. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10604 · Cited by 20
Tsering, W., Hery, G. P., Phillips, J. L., Lolo, K., Bathe, T., Villareal, J. A. B., Ruan, I. Y., & Prokop, S. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01688-6 · Cited by 20
Optogenetic and chemogenetic approaches for modeling neurological disorders in vivo
Krut’, V. G., Kalinichenko, A. L., Maltsev, D. I., Jappy, D., Shevchenko, E. K., Podgorny, O. V., & Belousov, V. V. (2024) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2024.102600 · Cited by 20
Rahimi, A., Sameei, P., Mousavi, S., Ghaderi, K., Hassani, A., Hassani, S., & Alipour, S. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04143-2 · Cited by 18
Homocysteine Thiolactone Detoxifying Enzymes and Alzheimer’s Disease
Jakubowski, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158095 · Cited by 19
Mathematical models on Alzheimer's disease and its treatment: A review
Maji, M., & Khajanchi, S. (2025) · Physics of Life Reviews · doi:10.1016/j.plrev.2025.01.004 · Cited by 19
Kang, T. H., & Friedmann, T. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.01.042 · Cited by 18
Jin, C., Zhang, L., Xian, Y., Liu, X., Wu, Y., Zhang, F., Zhu, J., Zhang, G., Chen, C., Gong, R., et al. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.01.029 · Cited by 19
A Missense Variant in TREML2 Reduces Risk of Alzheimer’s Disease in a Han Chinese Population
Jiang, T., Wan, Y., Zhou, J., Tan, M., Huang, Q., Zhu, X., Lu, H., Wang, H.-F., Chen, Q., Tan, L., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9706-8 · Cited by 18
Chang, Y., Mori, E., Suzuki, M., Ikeda, M., Huang, C., Lee, J., Chang, W., & Chang, C. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.101621 · Cited by 19
Immunotherapy Targeting Amyloid-ß Peptides in Alzheimer’s Disease
Zampar, S., & Wirths, O. (2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020.ch2 · Cited by 27
Terrill, S. E., Colvin, B. A., Davenport, R. E., & Nichols, M. R. (2016) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2016.03.017 · Cited by 18
The Integrative Five-Fluid Circulation System in the Human Body
Fung, P. C. W., & Kong, R. K. C. (2016) · Open Journal of Molecular and Integrative Physiology · doi:10.4236/ojmip.2016.64005 · Cited by 20
Acquisition and reversal of visual discrimination learning in APPSwDI/Nos2−/− (CVN) mice
Piiponniemi, T. O., Bragge, T., Vauhkonen, E. E., Vartiainen, P., Puoliväli, J. T., Sweeney, P. J., & Kopanitsa, M. V. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.04.049 · Cited by 22
Multi-tissue polygenic models for transcriptome-wide association studiesPreprint
Park, Y., Sarkar, A., Bhutani, K., & Kellis, M. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/107623 · Cited by 20
Metadata
- Authors
- Tanzi, R. E.
- Affiliations
- Harvard University (US)
- Corresponding author
- Tanzi, R. E.
- ORCID
- Tanzi, R. E.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2012-07-25
- Volume
- 2
- Issue
- 10
- Pages
- a006296-a006296
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W4233829850
- Cited by
- 727
- References
- 55
- Citations by year
- 2026: 40 · 2025: 55 · 2024: 58 · 2023: 70 · 2022: 54 · 2021: 49 · 2020: 54 · 2019: 40 · 2018: 42 · 2017: 55 · 2016: 60 · 2015: 52 · 2014: 61 · 2013: 32 · 2012: 5
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease, genetic susceptibility, familial Alzheimer's disease, APP mutations, presenilin 1, presenilin 2, apolipoprotein E, APOE ε4, late-onset Alzheimer's disease, twin and family studies, genome-wide association study, candidate genes, heritability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.